Il­lu­mi­na re­ports stronger-than-ex­pect­ed growth, in­di­cates Grail di­vesti­ture still in ear­ly stages: #JPM24

Il­lu­mi­na’s stock rose af­ter re­port­ing stronger quar­ter­ly rev­enue than ex­pect­ed, while com­pa­ny ex­ec­u­tives dur­ing the JP Mor­gan Health­care Con­fer­ence in­di­cat­ed can­cer-test­ing sub­sidiary Grail won’t be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.